Emerging therapies: The potential roles SGLT2 inhibitors, GLP1 agonists, and ARNI therapy for ARNI pulmonary hypertension
Sign Up to like & getrecommendations! Published in 2022 at "Pulmonary Circulation"
DOI: 10.1002/pul2.12028
Abstract: Abstract Pulmonary hypertension (PH) is a highly morbid condition. PH due to left heart disease (PH‐LHD) has no specific therapies and pulmonary arterial hypertension (PAH) has substantial residual risk despite several approved therapies. Multiple lines… read more here.
Keywords: pulmonary hypertension; inhibitors glp1; sglt2 inhibitors; glp1 agonists ... See more keywords
Cardiovascular prevention with GLP1 agonists in high or very-high cardiovascular risk irrespective of diabetes
Sign Up to like & getrecommendations! Published in 2024 at "European Heart Journal"
DOI: 10.1093/eurheartj/ehae666.2775
Abstract: Patients with established cardiovascular disease have an increased risk of stroke and myocardial infarction, even in the absence of atrial fibrillation. Several trials have analyzed the effect of glucagon-like peptide-1 receptor (GLP1) agonists in patients… read more here.
Keywords: high cardiovascular; glp1 agonists; non fatal; glp1 ... See more keywords